This segment focuses on the research, development, and clinical trials of Plinabulin, a selective immune-modulating microtubule-binding agent. Plinabulin is being developed for the prevention of chemotherapy-induced neutropenia (CIN) and the treatment of non-small cell lung cancer (NSCLC). Research and development activities include Phase III clinical trials, combination therapies with immuno-oncology agents like nivolumab and ipilimumab, and exploring its use in combination with radiation therapy. The therapeutic areas covered are primarily oncology, specifically NSCLC and other cancers. The goal is to improve patient outcomes by providing effective cancer treatments with reduced side effects. Market positioning involves competing in the immuno-oncology space with a focus on innovative approaches. Future opportunities include expanding the indications for Plinabulin and securing regulatory approvals. Partnerships and collaborations are crucial for clinical trial execution and commercialization.

SEED Therapeutics, a subsidiary of BeyondSpring, is dedicated to the discovery and development of novel molecular glue degraders for neurodegeneration and oncology indications. This segment leverages cutting-edge technologies to identify and develop targeted protein degradation (TPD) 2.0 therapies. Research and development activities include preclinical studies, target validation, and the design of molecular glue degraders. The therapeutic areas covered include oncology and neurodegenerative diseases. The aim is to address unmet medical needs by developing innovative therapies that can selectively degrade disease-causing proteins. Market positioning involves competing in the rapidly evolving field of targeted protein degradation. Future opportunities include expanding the pipeline of molecular glue degraders and securing strategic partnerships. Collaborations with companies like Eli Lilly and Eisai are key to advancing research and development efforts.